Applied Genetic Technologies Stock Forecast, Price & News

+0.05 (+1.34 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume394,501 shs
Average Volume928,625 shs
Market Capitalization$162.06 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AGTC News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

Applied Genetic Technologies logo

About Applied Genetic Technologies

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.59 out of 5 stars

Medical Sector

937th out of 4,434 stocks

Biological Products, Except Diagnostic Industry

131st out of 424 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions

Is Applied Genetic Technologies a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Applied Genetic Technologies stock.
View analyst ratings for Applied Genetic Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Applied Genetic Technologies?

Wall Street analysts have given Applied Genetic Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Applied Genetic Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Applied Genetic Technologies?

Applied Genetic Technologies saw a decrease in short interest in June. As of June 30th, there was short interest totaling 3,860,000 shares, a decrease of 27.6% from the June 15th total of 5,330,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the short-interest ratio is presently 2.8 days. Approximately 10.1% of the company's stock are short sold.
View Applied Genetic Technologies' Short Interest

When is Applied Genetic Technologies' next earnings date?

Applied Genetic Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, September 8th 2021.
View our earnings forecast for Applied Genetic Technologies

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) issued its quarterly earnings data on Sunday, May, 16th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.41) by $0.01.
View Applied Genetic Technologies' earnings history

How has Applied Genetic Technologies' stock been impacted by Coronavirus (COVID-19)?

Applied Genetic Technologies' stock was trading at $3.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AGTC shares have decreased by 1.3% and is now trading at $3.79.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AGTC?

6 equities research analysts have issued 1-year price objectives for Applied Genetic Technologies' stock. Their forecasts range from $11.00 to $35.00. On average, they expect Applied Genetic Technologies' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 401.3% from the stock's current price.
View analysts' price targets for Applied Genetic Technologies
or view top-rated stocks among Wall Street analysts.

Who are Applied Genetic Technologies' key executives?

Applied Genetic Technologies' management team includes the following people:
  • Ms. Susan B. Washer, Pres, CEO & Director (Age 60, Pay $795.26k)
  • Mr. Stephen W. Potter, VP & Chief Bus. Officer (Age 65, Pay $486.77k)
  • Dr. Matthew Feinsod, Exec. VP of Global Strategy & Devel. (Age 50, Pay $549.67k)
  • Dr. Nicholas Muzyczka, Co-Founder
  • Dr. Barry J. Byrne, Co-Founder
  • Dr. William W. Hauswirth, Co-Founder & Member of Ophthalmology Scientific Advisory Board
  • Dr. Richard Jude Samulski, Co-Founder
  • Dr. Terence R. Flotte, Co-Founder
  • Mr. Gerald Anthony Reynolds, Chief Accounting Officer, Principal Accounting Officer & Treasurer
  • Ms. Janet C. Rae RAC, Sr. VP of Global Regulatory & Quality

Who are some of Applied Genetic Technologies' key competitors?

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $3.79.

How much money does Applied Genetic Technologies make?

Applied Genetic Technologies has a market capitalization of $162.06 million and generates $2.45 million in revenue each year. The biotechnology company earns $-45,890,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How many employees does Applied Genetic Technologies have?

Applied Genetic Technologies employs 83 workers across the globe.

What is Applied Genetic Technologies' official website?

The official website for Applied Genetic Technologies is

Where are Applied Genetic Technologies' headquarters?

Applied Genetic Technologies is headquartered at 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.